

ANSWERING REVIEWERS



July 25, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 4071-review.doc).

Title: De novo combination of lamivudine and adefovir dipivoxil versus entecavir monotherapy for the treatment of Naïve patients with hepatitis B virus-related decompensated cirrhosis: a two-year study

Author: Jiangshan Lian, Linyan Zeng, Jianyang Chen, Hongyu Jia, Yimin Zhang, Dairong Xiang, Liang Yu, Jianhua Hu, Yingfeng Lu, Ling Zheng, Lanjuan Li, Yida Yang

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 4071

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer 1

To reviewer 1.

- 1) Because we didn't detect the genotype of our patients with HBV-related decompensated liver cirrhosis. In China, the predominant genotypes are B and C, we didn't see the difference regarding the efficacy of antiviral therapy between genotype B and C.
- 2) In this study we used reagents made by Shanghai ZJ Bio-Tech Co.,Ltd. in China.
- 3) So HBV DNA is expressed by copies. In the next study we will use IU.
- 4) As mention by the reviewer, it is true the recent EASL guideline 1 mg ETV should be given to the patients with HBV-related decompensated liver cirrhosis referenced from Liaw et al 2009 results, but in their study included lamivudine resistant patients which should be given 1 mg ETV fro rescue treatment. In our study all patient never received antiviral before they were recruited.
- 5) Because all the patients in this study are decompensated liver cirrhosis, it is dangerous for us to do biopsy. So we didn't evaluate the pathologic efficacy of antiviral therapy as the same as other studies.
- 6) We corrected the mistake of the age.
- 7) ULN have been changed to upper limit of normal.
- 8) Because the space limit, we didn't add normal of ALT, Alb, et al in the Table. All the value are the same as international standard.
- 9) All the papers about antiviral effect for HBV-related decompensated liver cirrhosis are relative new, most of the reference are published after 2008.
- 10) Reference 9 has also been corrected.


To Reviewer 2

- 1) We tried our best to modify the paper.
- 2) We added the methods for HBV DNA, HBeAg, HBsAg, et al.
- 3) We added the discussion section of Carey and Harrison's review about antiviral therapy of HBV infection.

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Yida Yang' in a cursive, flowing script.

Yida Yang, MD, PhD
Dept. of Infectious Diseases
1st Affiliated Hospital School of Medicine
Zhejiang University
Hangzhou, Zhejiang 310003
China
E-mail: yangyida65@163.com